Crinetics Pharmaceuticals to Participate in December Investor Conferences

Dr. Scott Struthers and Dr. Alan Krasner present at 32nd annual Piper Sandler Healthcare Conference December 1st-3rd, 2020 Webcast available until December 3rd.

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

“Dr. Trainer is a global leader in the endocrine community who has treated patients, published extensively and educated physicians on the identification and treatment of endocrine disease, particularly in the area of neuroendocrinology,” said Alan S. Krasner, M.D., Chief Medical Officer of Crinetics.

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for Treatment of Acromegaly

Crinetics hosts a virtual Key Opinion Leader (KOL) meeting on oral paltusotine for the treatment of acromegaly on Friday, November 20, 2020 at 11:00 am Eastern Time. Peter Trainer, MD and Monica Roberto Gadelha, MD, PhD discuss implications of Phase 2 ACROBAT studies with oral paltusotine.

Third Quarter 2020 Financial Results and Corporate Update

Positive topline results for Phase 2 trials of oral paltusotine (acromegaly), CRN04777 received Rare Pediatric Disease Designation (congenital hyperinsulinism)

ACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint

Crinetics announces Paltusotine (for treatment of acromegaly) was observed to be safe and well-tolerated among the 60 participants in the ACROBAT Edge and ACROBAT Evolve Studies.